Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Accounts Payables: 2017-2025

Historic Accounts Payables for Denali Therapeutics (DNLI) over the last 8 years, with Sep 2025 value amounting to $6.7 million.

  • Denali Therapeutics' Accounts Payables fell 29.70% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year decrease of 29.70%. This contributed to the annual value of $11.1 million for FY2024, which is 17.44% up from last year.
  • According to the latest figures from Q3 2025, Denali Therapeutics' Accounts Payables is $6.7 million, which was down 37.80% from $10.8 million recorded in Q2 2025.
  • In the past 5 years, Denali Therapeutics' Accounts Payables ranged from a high of $13.9 million in Q2 2024 and a low of $1.6 million during Q1 2021.
  • Moreover, its 3-year median value for Accounts Payables was $9.6 million (2024), whereas its average is $10.0 million.
  • Per our database at Business Quant, Denali Therapeutics' Accounts Payables skyrocketed by 346.22% in 2021 and then slumped by 41.62% in 2022.
  • Denali Therapeutics' Accounts Payables (Quarterly) stood at $4.8 million in 2021, then crashed by 41.62% to $2.8 million in 2022, then surged by 239.89% to $9.5 million in 2023, then climbed by 17.44% to $11.1 million in 2024, then decreased by 29.70% to $6.7 million in 2025.
  • Its Accounts Payables was $6.7 million in Q3 2025, compared to $10.8 million in Q2 2025 and $8.5 million in Q1 2025.